Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study

被引：4
|
作者：
Khuri, F. R.
Owonikoko, T. K.
Subramanian, J.
Sica, G.
Behera, M.
Saba, N. F.
Chen, Z.
Tighiouart, M.
Shin, D. M.
Sun, S.
Fu, R.
Gal, A.
Govindan, R.
Ramalingam, S. S.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e13601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Behera, Madhusmita
    Subramanian, Janakiraman
    Saba, Nabil F.
    Kono, Scott A.
    Gal, Anthony A.
    Sica, Gabriel
    Harvey, R. Donald
    Chen, Zhengjia
    Klass, Carmen M.
    Shin, Dong M.
    Fu, Haian
    Sun, Shi-yong R.
    Govindan, Ramaswamy
    Khuri, Fadlo R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 369 - 372
  • [2] Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
    Papadimitrakopoulou, Vassiliki A.
    Soria, Jean-Charles
    Jappe, Annette
    Jehl, Valentine
    Klimovsky, Judith
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1594 - 1601
  • [3] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Bepler, G.
    Oh, Y.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Herbst, R. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Oh, Y.
    Herbst, R.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Bepler, G.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 35 - 35
  • [5] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    [J]. Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [6] Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer : a pilot study
    Nishimura, Naoki
    Sugiura, Rika
    Ueda, Hirotaka
    Ono, Hiroshi
    Horinouchi, Hidehito
    Uchiyama, Noboru
    Chohnabayashi, Naohiko
    [J]. JOURNAL OF MEDICAL INVESTIGATION, 2008, 55 (3-4): : 260 - 266
  • [7] Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
    Kotake, Mie
    Kuwako, Tomohito
    Imai, Hisao
    Tomizawa, Yoshio
    Kaira, Kyoichi
    Yoshii, Akihiro
    Ochiai, Mai
    Miura, Yosuke
    Osaki, Takashi
    Sakurai, Reiko
    Takei, Kousuke
    Minato, Koichi
    Saito, Ryusei
    [J]. CHEMOTHERAPY, 2020, 65 (1-2): : 21 - 28
  • [8] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    [J]. JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [9] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    [J]. ONCOLOGIST, 2008, 13 : 14 - 20
  • [10] A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Harvey, Donald
    Saba, Nabil F.
    Kauh, John
    Shin Dong M
    Sun Shi-Yong
    Browning, Karen
    Tighiouart, Mourad
    Khuri, Fadlo R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S594 - S595
12345